SHC vs CRL

For growth investors, Sotera Health Company (SHC) is the stronger pick with 5.

7% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Sotera Health Company (SHC) offers the better valuation at 58. 0x trailing P/E (16. 3x forward), making it the more compelling value choice. Analysts rate Sotera Health Company (SHC) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Sotera Health Company is actually cheaper at 16.

3x.

Over the past 5 years, Sotera Health Company (SHC) delivered a total return of -36.

3%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: CRL returned +119. 2% versus SHC's -37. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sotera Health Company (SHC) is the lower-risk stock at 1.

32β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 15% more volatile than SHC relative to the S&P 500. On balance sheet safety, Charles River Laboratories International, Inc. (CRL) carries a lower debt/equity ratio of 95% versus 4% for Sotera Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sotera Health Company (SHC) is pulling ahead at 5.

7% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Sotera Health Company grew EPS 68. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, SHC leads at 5. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sotera Health Company (SHC) is the more profitable company, earning 6.

7% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 6. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHC leads at 33. 8% versus 12. 6% for CRL. At the gross margin level — before operating expenses — SHC leads at 55. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sotera Health Company (SHC) trades at 16.

3x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 0. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SHC: 40. 4% to $22. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sotera Health Company (SHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SHC: -37. 6%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.